Project Grant R43DK142506
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $325K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- This $291,949 Project Grant was awarded on September 15, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant was awarded to Biosettia Inc. (UEI: GZM5S2UYEGD2) located in San Diego, CA to support research aimed at using deep sequencing to measure variants of the endogenous retrovirus (ERV) GAG gene as potential biomarkers for type 1 diabetes. The project seeks...
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $284,517 Project Grant (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Electronic Biosciences, Inc. to develop a point-of-care diagnostic assay for detecting autoantibodies associated with type 1 diabetes (T1D). This project aims to leverage nanopore technology to create a rapid, cost-effective test for screening populations, especially children, for T1D biomarkers that appear...
- This $324,984 Project Grant was awarded on August 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Syntis Bio Inc., is developing an innovative oral therapy for treating homocystinuria, a rare metabolic disorder. The project involves optimizing a formulation that combines a protease-stable enzyme (methionine-gamma-lyase) with a...
- This federal Project Grant award of $568,075.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award to Brigham Young University aims to determine the role of the transcription factor NR4A1 in the pathways that expand functional beta cell mass, which is critical for treating type 1 and type 2 diabetes. The research seeks to understand how NR4A1 is...
- This federal Project Grant award of $444,867.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the UPR transducer XBP1 in pancreatic beta cell survival and function under metabolic stress. The research will use a novel mouse model to elucidate the pathological role of XBP1s in beta cell integrity under metabolic stress, in order to...
- This federal Project Grant award in the amount of $1,428,186.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Massachusetts. The project aims to investigate the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans, which has implications for understanding the early...
- This federal Project Grant award of $304,993 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Immunowork LLC, located in Monrovia, CA. The award supports a research project to quantify peripheral blood antigen-specific memory B cells as a new biomarker in patients with PLA2R-associated membranous nephropathy, a common form of nephrotic syndrome. The goal...